News Headlines Article

Hospitals, cancer centers chafe at CMS’ approach to national CAR-T coverage
Modern Healthcare

With a decision less than a month away, hospital and cancer center executives hope to persuade the CMS to be more flexible in covering a new and costly cancer treatment that’s still evolving.

The CMS in February proposed that it make a national coverage determination for chimeric antigen receptor T-cell therapy, or CAR-T, that boosts a person’s immune system cells to combat cancer.

A decision is expected by the end of May for a treatment that can cost as much as $1 million.